4 - LUMINEX CORP (0001033905) (Issuer)

4 - LUMINEX CORP (0001033905) (Issuer)

4 - LUMINEX CORP (0001033905) (Issuer)

4 - LUMINEX CORP (0001033905) (Issuer)

4 - LUMINEX CORP (0001033905) (Issuer)

4 - LUMINEX CORP (0001033905) (Issuer)

4 - LUMINEX CORP (0001033905) (Issuer)

4 - LUMINEX CORP (0001033905) (Issuer)

4 - LUMINEX CORP (0001033905) (Issuer)

4 - LUMINEX CORP (0001033905) (Issuer)

15-12G - LUMINEX CORP (0001033905) (Filer)

S-8 POS - LUMINEX CORP (0001033905) (Filer)

S-8 POS - LUMINEX CORP (0001033905) (Filer)

S-8 POS - LUMINEX CORP (0001033905) (Filer)

S-8 POS - LUMINEX CORP (0001033905) (Filer)

S-8 POS - LUMINEX CORP (0001033905) (Filer)

S-8 POS - LUMINEX CORP (0001033905) (Filer)

S-8 POS - LUMINEX CORP (0001033905) (Filer)

S-8 POS - LUMINEX CORP (0001033905) (Filer)

S-8 POS - LUMINEX CORP (0001033905) (Filer)

Piper Sandler downgraded Luminex from Overweight to Neutral and set a new price target of $37.00 from $38.00 previously

BTIG downgraded Luminex from Buy to Neutral

NEW YORK, July 12, 2021 /PRNewswire/ -- Middlesex Water Co. (NASD: MSEX) will replace Luminex Corp. (NASD: LMNX) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, July 15. DiaSorin S.p.A. is acquiring Luminex in a deal expected to be completed soon pending final closing conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 15, 2021 S&P SmallCap 600 Addition Middlesex Water MSEX Utilities S&P SmallCap 600 Deletion Luminex LMNX Health Care For more information about S&P Dow Jones Indices, please visit www.spdji.com. ABOUT

AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10 per share of common stock payable on July 8, 2021 to stockholders of record as of the close of business June 17, 2021. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical

SALUGGIA, Italy, April 11, 2021 /PRNewswire/ -- DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation ((", Luminex", , NASDAQ:LMNX) for a price of USD 37.00 per share in an all-cash transaction. This corresponds to a total equity value of approximately USD 1.8 billion on a fully diluted basis and an enterprise value of approximately USD 1.8 billion. The cash consideration represents a c.23.1% premium to Luminex shareholders based on the unaffected closing stock price of Luminex on 24 February 2021 (the date prior to press rumors regarding a potentia

AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration for the company's new multi-analyte respiratory panel combining Flu A/B and respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target. The ARIES® Flu A/B & RSV+SARS-CoV-2 Assay can be run on all Luminex ARIES® Systems. This submission represents completion of a key milestone in a Luminex funding award from the Biomedical Advanced Research and Development Authority (BARDA), which helped support the rapid development and validation of the assay. Respiratory infections such as COVID-1

AUSTIN, Texas, March 9, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, Chairman, CEO & President, and Harriss Currie, Senior Vice President and CFO, plan to participate at the 2021 Barclays Global Healthcare Conference on March 10, 2021 at 8:35 a.m. Eastern Time. A live webcast of the Luminex presentation may be accessed at the company's website at http://www.luminexcorp.com. The presentation will be archived for six months on the website using the 'replay' link. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions appli

AUSTIN, Texas, March 4, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new expanded version of its NxTAG® Respiratory Pathogen Panel (RPP) that includes the SARS-CoV-2 virus for high-throughput respiratory testing. The new test is a combination of the company's original NxTAG RPP, an FDA-cleared in vitro diagnostic for syndromic respiratory infection testing, and SARS-CoV-2. Respiratory infections such as COVID-19 and influenza can be challenging to differentiate and diagnose because they often have overlapping symptoms. NxTAG RPP is a multiplex, high-throug

AUSTIN, Texas, Feb. 19, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. These funds will support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target that can be run on all ARIES® Systems. These 6- and 12-cassette systems are automated molecular diagnostic platforms used in moderate- and high-complexity labs with a number of FDA c

AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020. All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP"). CURRENT FINANCIAL HIGHLIGHTS Record revenue for the fourth quarter of $111.4M, a 23% increase over Q4 2019, and record revenue for the year of $417.4M, up 25% vs. 2019, driven primarily by growth associated with the COVID-19 global pandemic Gross margins of 58% for the quarter and 59% for the full year, an improvement of 3 and 4 percentage points, respectively, vs. Q4 and full-year 2019 Operating margin of $10.5M or 9

AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2021 of $0.10 per share of common stock payable on April 15, 2021 to stockholders of record as of the close of business March 25, 2021. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We a

AUSTIN, Texas, Jan. 27, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the fourth quarter ended December 31, 2020 on Monday, February 8, 2021. A press release announcing the results is scheduled for release after the close of trading on that date. Management will hold a conference call to discuss the operating highlights and financial results for the fourth quarter ended December 31, 2020 on February 8, 2021, at 5:00 p.m. Eastern Time. The conference call will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the website, go to the About Luminex section and acces

AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10 per share of common stock payable on July 8, 2021 to stockholders of record as of the close of business June 17, 2021. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical

AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020. All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP"). CURRENT FINANCIAL HIGHLIGHTS Record revenue for the fourth quarter of $111.4M, a 23% increase over Q4 2019, and record revenue for the year of $417.4M, up 25% vs. 2019, driven primarily by growth associated with the COVID-19 global pandemic Gross margins of 58% for the quarter and 59% for the full year, an improvement of 3 and 4 percentage points, respectively, vs. Q4 and full-year 2019 Operating margin of $10.5M or 9

AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2021 of $0.10 per share of common stock payable on April 15, 2021 to stockholders of record as of the close of business March 25, 2021. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We a

AUSTIN, Texas, Dec. 7, 2020 /PRNewswire/ -- On December 3, 2020, Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors approved a $0.01 increase in the quarterly dividend, to $0.10 per share of common stock, payable on January 14, 2021 to stockholders of record as of the close of business December 23, 2021. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, a

SC 13G/A - LUMINEX CORP (0001033905) (Subject)

SC 13G/A - LUMINEX CORP (0001033905) (Subject)